Trials / Completed
CompletedNCT00398099
To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)
Clinical Evaluation for the Efficacy, Safety, Tolerability & Medical Resource Utilization of Invanz (Ertapenem Sodium) Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To collect clinical response data with the use of ertapenem in approved indications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0826, ertapenem sodium / Duration of Treatment: 14 Days |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2006-11-10
- Last updated
- 2017-02-17
Source: ClinicalTrials.gov record NCT00398099. Inclusion in this directory is not an endorsement.